Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD276 (B7-H3 protein) (CD276 (also referred to as B7-H3))
- Target
- CD276 (also referred to as B7-H3)
- Molecular classification
- Immune checkpoint molecule, Cell surface glycoprotein, Member of the B7 family (B7-CD28 superfamily), Receptor ligand (though direct receptor remains unknown)
01
Overview
CD276 (B7-H3 protein) is a type I transmembrane glycoprotein and an immune checkpoint molecule belonging to the B7 family. Highly overexpressed in a broad range of human solid tumors, CD276 serves as a distinguishing marker for cancer stem-like cells, supporting tumor cell proliferation, migration, metabolic reprogramming, and immune evasion. Its expression correlates with tumor progression, metastatic capability, and poor prognosis. Therapeutic strategies targeting CD276 include monoclonal antibodies, bispecific antibodies, and CAR-T cells, which aim to block its immune-inhibitory effects and directly target cancer stem cells. The incomplete understanding of its specific receptors and occasional expression in normal tissue pose ongoing therapeutic challenges.
- Other names
- B7-H3CD276B7 homolog 3 protein
02
Mechanism of action
Immune checkpoint blockade, leading to restored T cell-mediated antitumor immunity; Antibody-dependent cell-mediated cytotoxicity (ADCC); Direct elimination of cancer stem cells; Downregulation of immune evasion pathways
03
Biological functions
Immune regulation (inhibitory checkpoint for T cell activation and proliferation)Tumor microenvironment modulationPromoting tumor cell proliferation and migrationStemness maintenance in cancer stem cellsPromotes epithelial-mesenchymal transition (EMT)Modulates metabolic reprogramming of cancer cells (glycolysis enhancement)
04
Disease associations
Cancer (especially solid tumors: head and neck squamous cell carcinoma, cervical carcinoma, colorectal cancer, etc.)Tumor progression and metastasisTumor immune evasionPoor prognosis marker
05
Safety considerations
Potential for immune-related adverse effects due to broad checkpoint functionOff-target toxicity; although CD276 expression is lower in normal tissues, possible expression in some healthy cells remains a safety considerationUnknown direct receptor: the precise physiological function and signaling axis of CD276 in non-malignant cells is incompletely understood
06
Interacting drugs
Anti-B7-H3 monoclonal antibodies (several mAbs are in clinical trials)
4 more in the full profile.
07
Biomarkers
CD276 expression level (for cancer stem cell enrichment and correlation with poor prognosis)Co-expression with BMI1, OCT4, SOX2 in stem-cell-like subsetsLymph node metastasis (higher CD276 expression in metastatic cells)
Beyond the preview
Go deeper on CD276 (B7-H3 protein) (CD276 (also referred to as B7-H3)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD276 (B7-H3 protein) (CD276 (also referred to as B7-H3)).